You cannot always win : molecular bases of the resistance of picornaviruses to win compounds

Munira Mustaffa, Nikolai Zhelev

Research output: Contribution to journalArticle

Abstract

The Picornaviridae family comprises a heterogeneous group of non-enveloped viruses with genome consisting of a single positive-sense RNA strand. Infections with picornaviruses are very common in humans, producing a spectrum of clinical outcomes, ranging from asymptomatic infection and mild respiratory illness, to meningitis, myocarditis, pericarditis, and enterovirus-induced septic syndrome. Most picornaviruses seem to develop resistance quite effectively against almost any chemotherapeutic agent that modern science has developed, presenting a truly formidable challenge to modern healthcare. For some time, it has been hoped that synthetic agents mimicking the naturally occurring sphingosine-like molecule occupying the hydrophobic pocket in the viral capsid may be useful as antiviral agents, but it has been repeatedly demonstrated that resistance to the pocket-binding antivirals develops quite rapidly and that viral strains dependent on the chemotherapeutic may emerge. Several pocket-binding pyrazole drugs have entered clinical trials so far, but as of now, none of these have been licensed by the FDA, despite the extensive clinical trials. Apparently, the search for means of prevention of infection with rhino- and enteroviruses or an etiotropic cure for the conditions related to infections with picornaviruses is still ongoing.
Original languageEnglish
Pages (from-to)2826 - 2828
Number of pages3
JournalBiotechnology and Biotechnological Equipment
Volume26
Issue number2
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Picornaviridae Infections
Picornaviridae
Enterovirus
Antiviral Agents
Clinical Trials
Rhinovirus
Asymptomatic Infections
Sphingosine
Pericarditis
Capsid
Myocarditis
Meningitis
Genome
RNA
Viruses
Delivery of Health Care
Infection
Pharmaceutical Preparations

Cite this

@article{7113ea75c7e4454aa6655fb85343efe8,
title = "You cannot always win : molecular bases of the resistance of picornaviruses to win compounds",
abstract = "The Picornaviridae family comprises a heterogeneous group of non-enveloped viruses with genome consisting of a single positive-sense RNA strand. Infections with picornaviruses are very common in humans, producing a spectrum of clinical outcomes, ranging from asymptomatic infection and mild respiratory illness, to meningitis, myocarditis, pericarditis, and enterovirus-induced septic syndrome. Most picornaviruses seem to develop resistance quite effectively against almost any chemotherapeutic agent that modern science has developed, presenting a truly formidable challenge to modern healthcare. For some time, it has been hoped that synthetic agents mimicking the naturally occurring sphingosine-like molecule occupying the hydrophobic pocket in the viral capsid may be useful as antiviral agents, but it has been repeatedly demonstrated that resistance to the pocket-binding antivirals develops quite rapidly and that viral strains dependent on the chemotherapeutic may emerge. Several pocket-binding pyrazole drugs have entered clinical trials so far, but as of now, none of these have been licensed by the FDA, despite the extensive clinical trials. Apparently, the search for means of prevention of infection with rhino- and enteroviruses or an etiotropic cure for the conditions related to infections with picornaviruses is still ongoing.",
author = "Munira Mustaffa and Nikolai Zhelev",
year = "2012",
month = "4",
doi = "10.5504/BBEQ.2012.0022",
language = "English",
volume = "26",
pages = "2826 -- 2828",
journal = "Biotechnology and Biotechnological Equipment",
issn = "1310-2818",
publisher = "Diagnosis Press Limited.",
number = "2",

}

You cannot always win : molecular bases of the resistance of picornaviruses to win compounds. / Mustaffa, Munira; Zhelev, Nikolai.

In: Biotechnology and Biotechnological Equipment, Vol. 26, No. 2, 04.2012, p. 2826 - 2828.

Research output: Contribution to journalArticle

TY - JOUR

T1 - You cannot always win : molecular bases of the resistance of picornaviruses to win compounds

AU - Mustaffa, Munira

AU - Zhelev, Nikolai

PY - 2012/4

Y1 - 2012/4

N2 - The Picornaviridae family comprises a heterogeneous group of non-enveloped viruses with genome consisting of a single positive-sense RNA strand. Infections with picornaviruses are very common in humans, producing a spectrum of clinical outcomes, ranging from asymptomatic infection and mild respiratory illness, to meningitis, myocarditis, pericarditis, and enterovirus-induced septic syndrome. Most picornaviruses seem to develop resistance quite effectively against almost any chemotherapeutic agent that modern science has developed, presenting a truly formidable challenge to modern healthcare. For some time, it has been hoped that synthetic agents mimicking the naturally occurring sphingosine-like molecule occupying the hydrophobic pocket in the viral capsid may be useful as antiviral agents, but it has been repeatedly demonstrated that resistance to the pocket-binding antivirals develops quite rapidly and that viral strains dependent on the chemotherapeutic may emerge. Several pocket-binding pyrazole drugs have entered clinical trials so far, but as of now, none of these have been licensed by the FDA, despite the extensive clinical trials. Apparently, the search for means of prevention of infection with rhino- and enteroviruses or an etiotropic cure for the conditions related to infections with picornaviruses is still ongoing.

AB - The Picornaviridae family comprises a heterogeneous group of non-enveloped viruses with genome consisting of a single positive-sense RNA strand. Infections with picornaviruses are very common in humans, producing a spectrum of clinical outcomes, ranging from asymptomatic infection and mild respiratory illness, to meningitis, myocarditis, pericarditis, and enterovirus-induced septic syndrome. Most picornaviruses seem to develop resistance quite effectively against almost any chemotherapeutic agent that modern science has developed, presenting a truly formidable challenge to modern healthcare. For some time, it has been hoped that synthetic agents mimicking the naturally occurring sphingosine-like molecule occupying the hydrophobic pocket in the viral capsid may be useful as antiviral agents, but it has been repeatedly demonstrated that resistance to the pocket-binding antivirals develops quite rapidly and that viral strains dependent on the chemotherapeutic may emerge. Several pocket-binding pyrazole drugs have entered clinical trials so far, but as of now, none of these have been licensed by the FDA, despite the extensive clinical trials. Apparently, the search for means of prevention of infection with rhino- and enteroviruses or an etiotropic cure for the conditions related to infections with picornaviruses is still ongoing.

U2 - 10.5504/BBEQ.2012.0022

DO - 10.5504/BBEQ.2012.0022

M3 - Article

VL - 26

SP - 2826

EP - 2828

JO - Biotechnology and Biotechnological Equipment

JF - Biotechnology and Biotechnological Equipment

SN - 1310-2818

IS - 2

ER -